16 September 2026 editorial review · Item
Non-invasive glucose monitoring (Apple, Samsung, Know Labs, Afon Glucowear): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Non-invasive glucose monitoring (Apple, Samsung, Know Labs, Afon Glucowear)
Scope and findings:
- Rechecked FDA no-authorized-watch/ring warning and calibration-dependent Raman research in type 2 diabetes. Does not establish a dosing-authorized noninvasive T1D CGM. Future Apple timing is external speculation, not primary verification.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.